Pharmacosmos drug beats competition as EU investigation into alleged slanderer Vifor continues

A new head-to-head study demonstrates that iron deficiency drug Monofer is better than Ferinject, a competing treatment developed by Vifor Pharma. An ongoing EU antitrust investigation makes the results even more important, says Pharmacosmos.

Photo: Pharmacosmos / PR

Danish company Pharmacosmos has shown in a head-to-head trial that its intravenous (IV) iron deficiency treatment, Monofer, is better than its closest competition on the market, Ferinject made by Swiss Vifor Pharma.

Victory may be even sweeter for the firm as the EU Commission has opened an antitrust investigation into whether Pharmacosmos has faced unfair conditions on the European market for years due to alleged disparaging attempts by the other firm concerning the safety of the two drugs.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs